ArticleBMC neurology2015

Assessment of immune functions and MRI disease activity in relapsing-remitting multiple sclerosis patients switching from natalizumab to fingolimod (ToFingo-Successor).

Luisa Klotz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.